erdafitinib: Clinical Trials

3 trials of erdafitinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 active not recruiting. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Recruiting 2, Active not recruiting 1

Follow erdafitinib: new trials by email Literature Review of erdafitinib trials Research Report on erdafitinib

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
TAR-210, Mitomycin C, Gemcitabine - Non-Muscle Invasive Bladder Neoplasms
Phase 3RecruitingJanssen Research & Development, LLC2202025-09-102026-11-03
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
TAR-210, Gemcitabine, MMC - Non-Muscle Invasive Bladder Neoplasms
Phase 3RecruitingJanssen Research & Development, LLC6412024-04-182026-11-03
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
Erdafitinib, Vinflunine, Docetaxel - Urothelial Cancer
Phase 3Active not recruitingJanssen Research & Development, LLC6292018-03-232026-11-03

Conditions studied

Non-Muscle Invasive Bladder Neoplasms (2)

Sponsors

Janssen Research & Development, LLC (3)

Countries

Argentina (3)  ·  Belgium (3)  ·  Brazil (3)  ·  China (3)  ·  France (3)  ·  Germany (3)  ·  Israel (3)  ·  Italy (3)  ·  Japan (3)  ·  South Korea (3)  ·  Spain (3)  ·  United Kingdom (3)  ·  United States (3)  ·  Austria (2)  ·  Greece (2)

Results publications

PMID 37870920

NIH funding

2017 (1), 2023 (1)